This trial is evaluating whether JAB-21822 (KRAS G12C inhibitor) will improve 4 primary outcomes and 6 secondary outcomes in patients with Cancer. Measurement will happen over the course of At the end of Cycle 1 (each cycle is 21 days).
This trial requires 100 total participants across 3 different treatment groups
This trial involves 3 different treatments. JAB-21822 (KRAS G12C Inhibitor) is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"Jab-21822 should be prescribed after other treatment options are considered. Jab-21822 should be used only as a last resort. After treatment has failed or undesirable side effects are observed, one should reconsider the use of jab-21822." - Anonymous Online Contributor
"Cancer incidence rates in the US are projected to decrease by about 5-7% between the 2000 and 2020 years after the present. Given the fact that cancer prevalence has declined substantially during the last four decades, this pattern of decreasing cancer incidence is the most plausible explanation for the significant increase in cancer mortality in the United States in recent decades. Data from a recent study suggests that even if the US has been successful in improving cancer survival and decreasing cancer incidence rates over the past 50 years, the incidence rates are still lower than those seen in developed countries in the last 25 years. A combination of decreasing cancer incidence, improved cancer survival, and declining cancer incidence rates is not likely to occur in the future, and it poses a growing concern for the US health care system." - Anonymous Online Contributor
"The current standard therapy of cancer management (surgery, radiotherapy, chemotherapy, and targeted agents) shows no cure for cancer. However, the quality of life, prognosis, and survival of patients can all be improved." - Anonymous Online Contributor
"About 1 in 10 cancers have a strong genetic link to exposure to the carcinogen. People are most affected by cancer in the same parts of the lung or colon at the same time of their lives. And there are multiple factors which increase a person's risk of developing cancer. There are many genes involved." - Anonymous Online Contributor
"Cancer treatments are based on factors such as type of cancer, tumor size, and how deep the malignancy goes into the body. Common treatments for cancer are surgery, radiation therapy, chemotherapy, targeted therapy, and a combination of these. For each treatment, there are specific side effects. These side effects may be temporary or permanent depending on the treatment.\n\nThe International Agency for Research on Cancer classifies cancers as either "cancer" or "other"." - Anonymous Online Contributor
"Cancers may present with unexplained weight loss, unexplained blood in the urine, unexplained pain, unexplained unexplained changes in appetite (such as weight loss) and unexplained tingling in fingers and toes.\n\nThere is a common misconception that most signs of cancer are caused by cancer. Signs of cancer are not necessarily caused by cancer, but can be caused by other diseases, including diabetes.\n\nThe four major signs of cancer are cancer being present, the seriousness of the disease, signs and symptoms of the disease, and the seriousness of the patient.\n\nThe four major signs of cancer are:\n1. Someone with cancer will eventually develop cancer." - Anonymous Online Contributor
"Cancer is the sixth leading cause of death and is one of the common forms of cancer found worldwide. It results from accumulated damage to cells and tissue. Cancer begins as a single cell, but can spread to other cells. Cancer can be divided into five main types: skin, colon, breast, lung, and prostate cancer. Each of these types of cancer has different risk factors and the most common risk factors are smoking, excess weight, lack of physical exercise and exposure to ultraviolet (UV) radiation, and certain inherited disorders, among others. The most commonly diagnosed cancers among men are prostate cancer, skin cancer and colorectal cancer." - Anonymous Online Contributor
"The data demonstrate that jab-21822 is effective in overcoming the g12c mutant checkpoint pathway, reducing growth to the cells expressing the g12c mutation and enhancing their antitumor activity in vitro and in vivo. Jab-21822 may be a promising drug candidate for treating g12c mutant tumors in patients with advanced cancers." - Anonymous Online Contributor
"jab-21822 is a promising new small molecule KrasG12c (G13K) inhibitor that can enter cell lines, induce cell death and inhibit growth. jab-21822, when given to patients with advanced cancer in phase 1 trial, resulted in a 5-fold increase in patient progression-free survival compared to chemotherapy without jab-21822. jab-21822 has also shown significant antitumor activity in cultured cell lines. jab-21822 is well tolerated in clinical trials and in preclinical in vivo models; has a broad therapeutic window in vivo and in vitro and induces apoptosis in cancer stem cells through the extrinsic apoptotic cell pathway." - Anonymous Online Contributor
"Cancer is found almost as often in first-degree relatives as in nonrelatives and has high concordance among multiple cancers, indicating some commonality among the genetic modifiers." - Anonymous Online Contributor
"Results from a recent paper of the current latest studies cannot be assumed and only the results of the randomized controlled trials can be used. More studies have been done on [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) than on lung cancer. A larger number of randomized controlled trials, or meta-analyses have also been done on prostate cancer. Results in [breast cancer](https://www.withpower.com/clinical-trials/breast-cancer) for breast, and colon cancer show inconclusive results. In 2007, the British Cancer Foundation (United Kingdom) published results of a large multinational study on colon and rectal cancer. The study was undertaken to investigate whether vitamin D levels, folate and selenium supplements, and red wine may reduce the risk of colorectal cancer." - Anonymous Online Contributor
"Combination therapies, which included jab-21822 and other agents, were effective in inhibiting growth of most lung cancers and a panel of solid tumors. The addition of jab-21822 to other agents has been feasible in various patient populations." - Anonymous Online Contributor